At Fall Clinical 2026, Aaron S. Farberg, MD, shares how gene expression testing guides melanoma and atopic dermatitis care and what Ameluz PDT adds.
News|Articles|June 3, 2026
7 Dermatology Headlines You Missed in May 2026
Author(s)Tim Smith
Fact checked by: Ryan Livingston
This installment of our Month in Review series highlights top news headlines and podcast updates in dermatology from May 2026.
Advertisement
Advertisement
In May 2026, the HCPLive editorial team highlighted many different developments across the
Related to this article
A roundup of updates spanning PsO, atopic dermatitis, alopecia areata, vitiligo, palmoplantar pustulosis, cutaneous sarcoidosis, and discoid lupus.
Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.
Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.
In ADtouch, lebrikizumab improved clearance, itch, and pain in hand and foot atopic dermatitis. Shawn Kwatra, MD, discusses what the data mean.
A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.
US claims data from Fall Clinical 2026 suggest hidradenitis suppurativa symptoms occur at similar rates in both sexes, hinting at underdiagnosis in males.
Catch up on HCPLive’s top EADV 2026 psoriasis coverage, from head-to-head TYK2 inhibitor data to 2-year oral IL-23 results in high-impact disease sites.
Advertisement
Advertisement